Literature DB >> 12574258

Multisite reproducibility of results obtained by two broth dilution methods for susceptibility testing of Mycobacterium avium complex.

Gail L Woods1, Natalie Williams-Bouyer, Richard J Wallace, Barbara A Brown-Elliott, Frank G Witebsky, Patricia S Conville, Marianne Plaunt, Geraldine Hall, Priscilla Aralar, Clark Inderlied.   

Abstract

A multicenter study was conducted to assess the interlaboratory reproducibility of susceptibility testing of Mycobacterium avium complex (MAC) by broth microdilution using two different media (cation-adjusted Mueller-Hinton broth with 5% oleic acid-albumin-dextrose-catalase and 7H9 broth with casein) and by macrodilution using the BACTEC 460TB and 12B media at pH 6.8 and 7.3 to 7.4. Ten well-characterized strains of MAC (four macrolide susceptible, six macrolide resistant) were tested against clarithromycin and azithromycin (the latter only by BACTEC 460TB, pH 6.8). At each site, strains were tested against clarithromycin three times on each of three separate days (nine testing events per isolate) by using a common lot of microdilution trays and BACTEC 12B medium, pH 6.8; strains were tested once on three separate days against clarithromycin in 12B medium at pH 7.3 to 7.4 and against azithromycin. Agreement among MICs (i.e., mode +/- 1 twofold dilution) was 100% for all strains and both drugs when BACTEC 460TB was used, regardless of the pH of the medium, but varied when microdilution with either medium was used, particularly with susceptible strains. Agreement based on interpretive category, with NCCLS-recommended breakpoints, was 100% for all strains with the BACTEC 460TB method (both drugs and both pH values) and with microdilution using 7H9 broth. With microdilution and Mueller-Hinton broth, agreement by interpretive category was 100% for eight isolates and >90% for two; errors occurred only in laboratories where personnel had minimal experience with this technique. MAC susceptibility testing may be performed by broth macrodilution or microdilution at either pH, with NCCLS-recommended interpretive breakpoints. However, because visual interpretation of broth microdilution end points is subjective, it is more prone to reader error; therefore, this method requires greater expertise than the BACTEC 460TB. Both techniques require appropriate validation and continued documentation of proficiency.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12574258      PMCID: PMC149684          DOI: 10.1128/JCM.41.2.627-631.2003

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  23 in total

Review 1.  Mycobacterium avium complex infection in the acquired immunodeficiency syndrome.

Authors:  C R Horsburgh
Journal:  N Engl J Med       Date:  1991-05-09       Impact factor: 91.245

2.  Azithromycin as treatment for disseminated Mycobacterium avium complex in AIDS patients.

Authors:  S L Koletar; A J Berry; M H Cynamon; J Jacobson; J S Currier; R R MacGregor; M W Dunne; D J Williams
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

3.  Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team.

Authors:  J S Currier; P L Williams; S L Koletar; S E Cohn; R L Murphy; A E Heald; R Hafner; E L Bassily; H M Lederman; C Knirsch; C A Benson; H Valdez; J A Aberg; J A McCutchan
Journal:  Ann Intern Med       Date:  2000-10-03       Impact factor: 25.391

4.  Impact of prophylaxis for Mycobacterium avium complex on bacterial infections in patients with advanced human immunodeficiency virus disease.

Authors:  J S Currier; P Williams; J Feinberg; S Becker; S Owens; C Fichtenbaum; C Benson
Journal:  Clin Infect Dis       Date:  2001-04-30       Impact factor: 9.079

5.  Rapid broth macrodilution method for determination of MICs for Mycobacterium avium isolates.

Authors:  S H Siddiqi; L B Heifets; M H Cynamon; N M Hooper; A Laszlo; J P Libonati; P J Lindholm-Levy; N Pearson
Journal:  J Clin Microbiol       Date:  1993-09       Impact factor: 5.948

Review 6.  The Mycobacterium avium complex.

Authors:  C B Inderlied; C A Kemper; L E Bermudez
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

7.  Clarithromycin minimal inhibitory and bactericidal concentrations against Mycobacterium avium.

Authors:  L B Heifets; P J Lindholm-Levy; R D Comstock
Journal:  Am Rev Respir Dis       Date:  1992-04

8.  Infection with Mycobacterium avium complex in patients without predisposing conditions.

Authors:  D S Prince; D D Peterson; R M Steiner; J E Gottlieb; R Scott; H L Israel; W G Figueroa; J E Fish
Journal:  N Engl J Med       Date:  1989-09-28       Impact factor: 91.245

9.  Polyclonal Mycobacterium avium complex infections in patients with nodular bronchiectasis.

Authors:  R J Wallace; Y Zhang; B A Brown; D Dawson; D T Murphy; R Wilson; D E Griffith
Journal:  Am J Respir Crit Care Med       Date:  1998-10       Impact factor: 21.405

10.  Activities of clarithromycin against eight slowly growing species of nontuberculous mycobacteria, determined by using a broth microdilution MIC system.

Authors:  B A Brown; R J Wallace; G O Onyi
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

View more
  3 in total

1.  Antimycobacterial agents differ with respect to their bacteriostatic versus bactericidal activities in relation to time of exposure, mycobacterial growth phase, and their use in combination.

Authors:  Irma A J M Bakker-Woudenberg; Wim van Vianen; Dick van Soolingen; Henri A Verbrugh; Michiel A van Agtmael
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

2.  Drug susceptibility testing of slowly growing non-tuberculous mycobacteria using slomyco test-system.

Authors:  Vitalii Litvinov; Marina Makarova; Ksenia Galkina; Elena Khachaturiants; Maria Krasnova; Lidia Guntupova; Svetlana Safonova
Journal:  PLoS One       Date:  2018-09-17       Impact factor: 3.240

Review 3.  Anti-Mycobacterial Drug Resistance in Japan: How to Approach This Problem?

Authors:  Keisuke Kamada; Satoshi Mitarai
Journal:  Antibiotics (Basel)       Date:  2021-12-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.